Reported about 17 hours ago
Analysts are optimistic about Pfizer Inc (NYSE:PFE), anticipating a rally in healthcare stocks following its acquisition of Metsera, a biopharmaceutical company focused on obesity treatments. Despite a 1% dip in stock price this year and some concerns over its research pipeline, experts like Evan Seigerman see potential for growth due to the company's favorable position with regulators and its dividend. However, some investment firms have exited their positions due to concerns about Pfizer's turnaround potential, suggesting a cautious approach for investors.
Source: YAHOO